MLF1IP promotes normal erythroid proliferation and is involved in the pathogenesis of polycythemia vera
Sign Up to like & getrecommendations! Published in 2017 at "FEBS Letters"
DOI: 10.1002/1873-3468.12587
Abstract: Myelodysplasia/myeloid leukemia factor 1‐interacting protein (MLF1IP) appears to be an erythroid lineage‐specific gene in mice; however, its role in normal erythropoiesis and erythropoietic disorders have not yet been elucidated. Here, we found that MLF1IP is… read more here.
Keywords: polycythemia vera; proliferation involved; mlf1ip promotes; erythroid proliferation ... See more keywords
Late‐Onset Chorea in JAK2‐Associated Essential Thrombocythemia
Sign Up to like & getrecommendations! Published in 2021 at "Movement Disorders Clinical Practice"
DOI: 10.1002/mdc3.13105
Abstract: Somatic mutations in JAK2 are associated with chronic myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis (PMF). The most common variant, Val617Phe (JAK2), accounts for >95% of polycythemia vera and 50%–60% of… read more here.
Keywords: late onset; jak2 associated; polycythemia vera; essential thrombocythemia ... See more keywords
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04839-2
Abstract: Polycythemia vera (PV) is a hematopoietic stem cell disorder characterized by janus kinase 2 (JAK2) mutations and an increased cardiovascular risk. Low-risk PV patients (those younger than 60 years of age and without thrombosis history)… read more here.
Keywords: treated glatiramer; successfully treated; risk; polycythemia vera ... See more keywords
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03929-9
Abstract: Fedratinib (SAR302503, TG101348) is an orally administered Janus kinase (JAK) 2-selective inhibitor that is being developed for the treatment of patients with myelofibrosis (MF). The objectives of this analysis were to develop a population pharmacokinetic… read more here.
Keywords: fedratinib; polycythemia vera; vera essential; patients myelofibrosis ... See more keywords
Cerebral intraparenchymal extramedullary hematopoiesis in polycythemia vera
Sign Up to like & getrecommendations! Published in 2019 at "Acta Neurologica Belgica"
DOI: 10.1007/s13760-019-01196-2
Abstract: Polycythemia vera (PV) is the most common myeloproliferative neoplasm, characterized by erythrocytosis, leukocytosis, and thrombocytosis and often associated with splenomegaly [1]. Neurological complications of PV are rare, but can include ischemic strokes, transient ischemic attacks… read more here.
Keywords: polycythemia vera; hematopoiesis; lesion; extramedullary hematopoiesis ... See more keywords
Lesson for the clinical nephrologist: renal involvement in a patient with polycythemia vera
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Nephrology"
DOI: 10.1007/s40620-022-01324-x
Abstract: A 67-year-old man with a 4-year history of polycythemia vera was referred to the nephrology clinic for evaluation of nephrotic range proteinuria. The patient was known to have had progressively increasing proteinuria for three years.… read more here.
Keywords: polycythemia vera; patient; nephrology; microscopy ... See more keywords
Polycythemia vera masked due to severe iron deficiency anemia.
Sign Up to like & getrecommendations! Published in 2018 at "Hematology/oncology and stem cell therapy"
DOI: 10.1016/j.hemonc.2016.08.007
Abstract: Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients present with its actual clinical manifestations. The most common findings are increased red cell mass and an increased leukocyte count with decreased… read more here.
Keywords: polycythemia vera; vera masked; due severe; polycythemia ... See more keywords
Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia research"
DOI: 10.1016/j.leukres.2017.01.032
Abstract: Polycythemia vera (PV) is characterized by erythropoiesis and JAK2-activating mutations, with increased risks of morbidity and mortality. Most patients with PV are iron deficient, and treatment often includes hematocrit control with phlebotomy, which may exacerbate… read more here.
Keywords: ruxolitinib; polycythemia vera; iron deficiency; best available ... See more keywords
A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia research"
DOI: 10.1016/j.leukres.2017.08.010
Abstract: Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency… read more here.
Keywords: polycythemia vera; essential thrombocythemia; myelofibrosis;
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
Sign Up to like & getrecommendations! Published in 2022 at "Leukemia research"
DOI: 10.1016/j.leukres.2022.106809
Abstract: Patients with polycythemia vera (PV) and essential thrombocythemia (ET) have increased thrombotic risk. This retrospective, real-world analysis of Medicare patients (age ≥ 65 years) newly diagnosed with high-risk PV or intermediate-/high-risk ET compared mortality risk among… read more here.
Keywords: risk; polycythemia vera; thrombotic events; mortality risk ... See more keywords
Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/leu.2017.298
Abstract: Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2 read more here.
Keywords: early concomitant; fibrotic progression; associated early; polycythemia vera ... See more keywords